{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:45:09Z","timestamp":1784202309070,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.semarthrit.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T01:43:11Z","timestamp":1560130991000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Chenyang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth I.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar K.","family":"Waljee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2019.06.001_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.06.001_bib0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.06.001_bib0003","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.06.001_bib0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"110136","key":"10.1016\/j.semarthrit.2019.06.001_bib0005","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"16","key":"10.1016\/j.semarthrit.2019.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"New Engl J Med"},{"issue":"10086","key":"10.1016\/j.semarthrit.2019.06.001_bib0007","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0008","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.semarthrit.2019.06.001_bib0009","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative evaluation of biologic therapy options for psoriasis: a Systematic review and network meta-analysis","volume":"137","author":"Jabbar-Lopez","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0010","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"10047","key":"10.1016\/j.semarthrit.2019.06.001_bib0011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","article-title":"Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis","volume":"388","author":"Cipriani","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.06.001_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","article-title":"Network meta-analyses should be the highest level of evidence in treatment guidelines","volume":"266","author":"Leucht","year":"2016","journal-title":"Eur Arch Psychiatry Clinical Neurosci"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.06.001_bib0013","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kex452","article-title":"Efficacy and safety of biologics targeting interleukin-6, -12\/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis","volume":"57","author":"Wu","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.06.001_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0015","article-title":"Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis","author":"Song","year":"2017","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.06.001_bib0016","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10067-016-3204-2","article-title":"Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis","volume":"35","author":"Ungprasert","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.06.001_bib0017","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2015.09.004","article-title":"Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis","volume":"45","author":"Ungprasert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.semarthrit.2019.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"New Engl J Med"},{"issue":"10136","key":"10.1016\/j.semarthrit.2019.06.001_bib0019","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.06.001_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0021","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"The BMJ"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.06.001_bib0022","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.06.001_bib0023","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.06.001_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.06.001_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clinical Epidemiol"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.06.001_bib0026","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheumatism"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.06.001_bib0027","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheumatic Dis"},{"issue":"24","key":"10.1016\/j.semarthrit.2019.06.001_bib0028","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"New England J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.06.001_bib0029","first-page":"1040\u201050","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"issue":"9227","key":"10.1016\/j.semarthrit.2019.06.001_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.06.001_bib0031","doi-asserted-by":"crossref","first-page":"2264\u201072","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheumatism"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.06.001_bib0032","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheumatism"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.06.001_bib0033","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0034","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-018-0011-1","article-title":"Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis","volume":"2","author":"Strand","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.06.001_bib0035","doi-asserted-by":"crossref","first-page":"79\u201087","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.06.001_bib0036","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus Adalimumab for Psoriatic Arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Therapy"},{"key":"10.1016\/j.semarthrit.2019.06.001_bib0037","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","author":"Araujo","year":"2018","journal-title":"Semin Arthritis Rheumatism"},{"issue":"8","key":"10.1016\/j.semarthrit.2019.06.001_bib0038","first-page":"821","article-title":"Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: results from Two Randomized, Phase 3 Trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"J Drugs Dermatol JDD"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.06.001_bib0039","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.06.001_bib0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.06.001_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2017","journal-title":"Ann Rheumatic Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219300447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219300447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:59:31Z","timestamp":1758733171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017219300447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0049017219300447"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}